What the societies say, in date order, newest first. No CETP inhibitor is in a guideline as a recommended therapy: the class has no approval and no positive outcomes trial yet. What the documents do carry is the reasoning that moved the field from raising HDL to lowering apoB.
cetpinhibition.org2026
Editorial position of this site, not a society document
A short statement of what the trial record supports, written so readers are not left inferring a society position that does not exist. No guideline recommends raising HDL cholesterol as a therapeutic goal, and the CETP trials are the main reason.
American College of Cardiology / American Heart Association and partner societies2026
Current
The 2026 United States multisociety dyslipidaemia guideline. Like its European counterpart it carries no recommendation for CETP inhibition; it is included because it defines the American treatment thresholds against which any future approval will be judged.
European Society of Cardiology / European Atherosclerosis Society2025
Current
The 2025 focused update to the European dyslipidaemia guidance. It predates any CETP approval, so the class appears as pipeline rather than practice; its relevance here is the treatment thresholds and combination-therapy logic that an approved oral add-on would slot into.
European Society of Cardiology / European Atherosclerosis Society2019
Current, with a 2025 focused update
The European dyslipidaemia guideline that entrenched the lower-is-better LDL-C position and set the goals every CETP inhibitor is now measured against. It contains no recommendation for CETP inhibition, because no such drug was approved or had a positive outcomes trial to its name.